Increased osteopontin expression in endometrial carcinoma is associated with better survival outcome by Al Maghrabi, Haneen et al.
73
ORIGINAL PAPER /  G y N E cO LO G y
Ginekologia Polska
2020, vol. 91, no. 2, 73–78
Copyright © 2020 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.2020.0020
Corresponding author:
Jaudah Al-Maghrabi
Department of Pathology, Faculty of Medicine, King Abdulaziz University, P.O. BOX 80205, Jeddah 21589, Kingdom of Saudi Arabia
e-mail: jalmgrabi@kau.edu.sa, tel.: 00-966-12-6401000 ext 17069, fax: 00-966-12-6408433
Increased osteopontin expression in endometrial 
carcinoma is associated with better survival outcome
Haneen Al-Maghrabi1 , Wafaey Gomaa2,3 , Jaudah Al-Maghrabi1,2
1Department of Pathology, King Faisal Specialist Hospital and Research centre, Jeddah, Saudi Arabia 
2Department of Pathology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia 
3Department of Pathology, Faculty of Medicine, Minia University, Al-Minia, Egypt
ABSTRACT
Objectives: Osteopontin (OPN) is a key extracellular matrix protein that is involved in cancer progression. The aim of the 
current study is to investigate the relation of OPN immunostaining in endometrial carcinoma with clinicopathological 
parameters.
Material and methods: Archival 71 endometrial carcinomas and 30 non-neoplastic endometrial tissues were obtained from 
the Department of Pathology at King Abdulaziz University Jeddah, Saudi Arabia. Tissue microarrays were constructed. Tissue 
sections were stained using anti-human OPN monoclonal antibody. Immunostaining results were recorded and analysed. 
Results: In non-neoplastic endometrial tissues, high (increased) OPN immunostaining was observed in 100%. In endome-
trial carcinoma, high (increased) OPN immunostaining was seen in 64.8% of cases. High (increased) OPN immunostaining 
was more frequent in non-neoplastic tissues than in endometrial carcinoma (p < 0.001). OPN immunostaining showed no 
association with histological type, FIGO tumour grade, tumour size, myometrial invasion, lymphovascular invasion, surgical 
resection margin or lymph node metastasis. On the other hand, high (increased) OPN immunostaining was associated with 
better overall survival [Log Rank (Mantel-Cox) = 4.385, p = 0.003].
Conclusions: In endometrial carcinoma, immunohistochemical staining of OPN could be a helpful tool in the prediction 
survival pattern. OPN immunostaining showed no association with most clinicopathological features. Further investigations 
both clinical and molecular are needed to explore the downstream of OPN in endometrial carcinoma.
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INTRODUCTION
Endometrial carcinoma (EC) is one of the most common 
malignant tumours of female genital system. While early 
diagnosed stages of EC can be cured by surgical resection 
only, advanced cases of EC can be complicated by distant 
organ metastasis and peritoneal involvement associated 
with poor patient free survival rate. Thus, understating the 
genetic pathophysiology pathway of EC play a crucial role in 
therapeutic management protocol of the disease [1]. Angio-
genesis of a tumour is associated with genes expression in 
human endometrial endothelial cells (HEECs) which can en-
hance the process of angiogenesis, increase tumour perme-
ability, rapid cell proliferation and increase metastatic rate. 
Osteopontin (OPN) was first discovered as one of CD44 li-
gands [2]. It is a 70-KDa particle of phosphorylated N-linked 
glycoprotein, which was primarily discovered in bone matrix. 
OPN can be found in the epithelial linings of salivary glands, 
sweat ducts, breast, bronchi, pancreas, gall bladder, urinary 
bladder, and reproductive systems [3]. OPN is a glycosylated 
phosphoprotein of the extracellular matrix particles, which 
contains nine consecutive aspartic acid residues, considered 
a highly acidic region named N-terminal signal [4]. It can be 
also detected in activated defence cells like macrophages, 
lymphocytes and leukocytes [5]. OPN has the capacity to 
bind with osteocalcin, type I collagen, and fibronectin [6]. 
It is also involved in many precise cellular processes like cel-
lular adhesions, tumourigenesis, angiogenesis, and tumours 
distant metastasis. Moreover, its overexpression can affect 
transduction of PI3 Kinase/AKT activation signalling pathway 
in various tumours which affect the cellular apoptosis [7]. 
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OPN overexpression is one of the phospho-glycoprotein 
(P-gp) with oncogenic potential in various body tumours 
[8, 9]. Many studies discussed the role of OPN in various 
epithelial malignancies such as breast, colon cancer, thyroid 
and melanoma [10–17]. 
However, more studies are needed to enlighten the role 
of OPN expression in EC. The aim of this study is to find out 
the relation OPN immunostaining with clinical and patho-
logical features of EC based tissue microarray.
MATERIAL AND METHODS
Patients
The study utilised paraffin wax tumour blocks from 71 pa-
tients diagnosed with endometrial carcinoma in the period 
from 2003–2012. Also paraffin blocks from 30 non-neoplastic 
endometrial tissues in the period from 1995–1998 (20 pro-
liferative endometrium and 10 secretory endometrium). All 
blocks were used from the archives of the Department of 
Pathology at King Abdulaziz University, Jeddah, Saudi Ara-
bia. Some clinicopathological characteristics of patients 
are listed in Table 1. For statistical purpose, FIGO stages 
were classified into limited to uterine corpus (FIGO Stage 
I and II) and beyond the uterine corpus (FIGO III and IV). 
Also grades were reclassified as low grade (grade I) and (grades 
II and III). Data is shown in Table 1. The study was done follow-
ing rules of the ethics committee of Faculty of Medicine, King 
Abdulaziz University, Saudi Arabia, and declaration of Helsinki.
Tissue Microarray
Archival paraffin-embedded endometrial carcinoma 
samples and neoplastic tissues were selected and the desired 
areas were marked on haematoxylin and eosin (H&E)-stained 
slides. Arrays were produced by retrieving cores (1.5 mm 
in diameter each) from marked areas of each ‘donor’ tissue 
block and brought into new recipient paraffin blocks. Tissue 
microarrays were constructed in an automated tissue mi-
croarrayer [TMA Master 1.14 SP3 (3D Histech Ltd. Budapest, 
Hungary)]. Placenta tissue was used for orientation [17, 18].
Immunohistochemistry
The constructed tissue microarray paraffin blocks were 
sliced at 4 μm. Tissues were mounted on positive-charged 
slides (Leica Microsystems Plus Slides). In an automated im-
munostained BenchMark XT, Ventana® Medical systems Inc., 
Tucson, AZ, USA) immunohistochemistry was performed. 
Slides were deparaffinised in xylene and rehydrated. Slides 
were incubated with pre-diluted CC1 (cell conditioning solu-
tion) for 60 minutes to perform pre-treatment. Polyclonal 
anti-human rabbit anti-osteopontin antibody (Spring™ 
Bioscience; Cat # E3284) was incubated at 37oC for 20 min-
utes. The detection kit was used from Ventana® I-view DAB. 
The slides were washed and Mayer’s haematoxylin was used 
as a counter stain. The appropriate negative and positive 
control slides were used.
Interpretation of OPN Immunostaining
The immunostained slides were examined by two pa-
thologists (HM, WG) and a semiquantitative approach was 
used including the percentage of OPN positive cells. The per-
centage of OPN positivity was scaled as follows; (1) 0–25%, 
Table 1. Clinicopathological features of endometrial carcinoma 
(n = 71)
Parameter Number (%)
Age
< 60 years 49 (69%)
> 60 years 22 (31%)
Histological type 
Endometrioid 66 (93%)
Serous 5 (7%)
FIGO tumour grade
Grade 1 44 (62%)
Grade 2 16 (22.5%)
Grade 3 11 (15.5%)
Tumour size
≤ 2 cm 35 (49.3%)
> 2 cm 36 (50.7%)
Myometrial invasion
< 50% 57 (80.3%)
≥ 50% 14 (19.7%)
Lymphovascular
Absent 68 (95.8%)
Present 3 (4.2%)
Surgical resection margin
Free 67 (94.4%)
Involved 4 (5.6%)
Lymph node metastasis
Absent 33 (46.5%)
Present 4 (5.6%)
Not sampled 34 (47.9%)
FIGO Staging
I 51 (71.8%)
II 7 (9.9%)
III 7 (9.9%)
IV 6 (8.5%)
Local Recurrence
Absent 60 (84.5%)
Present 11 (15.5%)
FIGO (International Federation of Gynaecology and Obstetrics) 
Stage I — tumour confined to corpus uteri  
IA — tumour limited to endometrium or invades less than one-half of the 
myometrium 
IB — tumour invades one-half or more of the myometrium  
Stage II — tumour invades stromal connective tissue of the cervix but does 
not extend beyond uterus 
Stage III — there is regional tumour spread. 
IIIA — tumour involves serosa and/or adnexa (direct extension or metastasis)  
IIIB — vaginal involvement (direct extension or metastasis) or parametrial 
involvement  
IIIC — the tumour involves regional lymph nodes 
IIIC1 — regional lymph node metastasis to pelvic lymph nodes  
IIIC2 — Regional lymph node metastasis to para-aortic lymph nodes, with or 
without positive pelvic lymph nodes  
Stage IV — the tumour invades contiguous organs or has metastasized to 
remote organ sites 
IVA — tumour invades bladder mucosa and/or bowel mucosa (bullous 
oedema is not sufficient to classify a tumour as T4)  
IVB — distant metastasis
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(2) 26–50%, (3) 50–100%. For cytoplasmic immunostaining; 
3 (heavy and intense brown immunostaining), 2 (brown 
immunostaining lighter than 3), 1 (brown immunostaining 
is weak), and 0 (no brown immunostaining). The result of 
summing percentage and intensity provided scores from 
1–6. For the statistical analysis, an OPN immunostaining 
score of 1–3 was considered as low (decreased) immu-
nostaining, and an OPN immunostaining score of 4–6 was 
considered as high (increased) immunostaining [19]. 
Statistical analysis
To study the variation between two groups of patients 
on one variable, the Mann Whitney test was used. Non-par-
ametric chi-square was used to test variance along one vari-
able. The survival differences and probabilities and the Log 
Rank test was tested by using the univariate Kaplan-Meier 
procedure was used. The end-point for patients was last 
seen or death. The model was controlled for confounding 
variables. Statistical procedures were performed using SPSS® 
Release 16.0. Statistical significance was determined at 
p value of ≤ 0.05 and was 2-sided.
RESULTS
Pattern of OPN immunostaining
Immunostaining of OPN was indicated by cytoplasmic 
brown colour in non-neoplastic and neoplastic endome-
trial (Fig. 1). In non-neoplastic endometrial tissues, high 
(increased) immunostaining was observed in all specimens 
(100%) while in EC was 98.5%. The incidence of increased 
OPN (high immunostaining) immunostaining was more fre-
quent in non-neoplastic tissues (100%) than in endometrial 
carcinoma (64.9%) (p < 0.001). In endometrial carcinoma, 
high (increased) OPN immunostaining was seen in 71.8 %. 
The occurrence of high (increased) OPN immunostaining 
was statistically more than low (decreased) immunostaining 
(p ≤ 0.001). Data is shown in Table 2.
Correlation of OPN immunostaining with 
clinicopathological features of EC
The present study revealed that there was no correlation 
between OPN immunostaining with most clinicopathologi-
cal features (data is represented in Table 3). 
Correlation of OPN immunostaining with 
survival outcomes 
On the other hand, high (increased) OPN immunostain-
ing in endometrial carcinoma was associated with better 
survival outcomes for overall survival (log-rank = 4.385, 
p = 0.003) (Fig. 2).
DISCUSSION
EC affects approximately 2–3% women worldwide [7]. 
The process of tumorigenesis in EC must be studied and un-
derstood in order to establish proper tumour management 
under convenient designed therapeutic standards. Previous 
reports stated the possible role of OPN in tumour progres-
sion and metastasis [20, 21].
Previously, reported that OPN is produced in higher 
levels in endometrial tumour cells than normal non meta-
static cells. OPN particles can negatively affect the consecu-
tive pathophysiology process of cellular adhesion, cellular 
migration, and invasion by αvβ3 receptors [7, 22]. Also, 
OPN can activate ERK1/2 and PI3K/ AKT signalling pathway 
leading to promotion in cellular migration, proliferation, and 
invasion due to increased MMP-2 expression [7]. Indeed, 
OPN can intercede in cell adhesion, and tumour colonies 
formation. The role of OPN is important to be studied as 
a prognostic marker in EC that might contribute to future 
Figure 1. Immunostaining of OPN in non-neoplastic endometrium 
and endometrial carcinoma 
OPN is shown in the cytoplasm of proliferative endometrium 
(A–100X), secretory endometrium (B-200X), well-differentiated 
endometrial carcinoma (C–200X), and in moderately differentiated 
endometrial carcinoma (D–200X). Immunohistochemical labelling 
was done using the anti-OPN antibody and diaminobenzidine used 
as the chromogen and haematoxylin as counterstain.
Table 2. Categories of OPN immunostaining in endometrial 
carcinoma and non-neoplastic endometrium
Endometrial 
carcinoma 
(n = 71)
Non-neoplastic 
endometrium 
(n = 30)
Low (decreased) immunostaining 25 (35.2%) 0 (0%)
High (increased) immunostaining 46 (64.8%) 30 (100%)
p value  < 0.001*  < 0.001*
*One sample non-parametric chi-square test
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therapeutic management of the disease. Only a few papers 
in the literature correlate OPN expression and its clinico-
pathological significant with EC. Some results were incon-
clusive due to limited sample size. 
In the present study, the immunostaining of OPN in nor-
mal endometrial tissue and in EC was carried on tissue micro-
array format to find out its correlation with clinicopathologi-
cal features and possible clinical implications on the disease. 
In non-neoplastic endometrial tissues, high (increased) OPN 
immunostaining was observed in all specimens (100%). 
The immunolocalisation of OPN in normal endometrial tis-
sue was reported before as strong cytoplasmic staining in 
both proliferative and secretory phases. This finding was 
attributed to the role of OPN in normal cell regulation of 
menstrual cycle process and maternal-foetal interface reac-
tion during foetal placental implantation [22–25]. We found 
that high (increased) OPN immunostaining was found in 
46 EC (64.8%), while low (decreased) OPN was reported in 
25 cases (35.2%). On the other hand, these studies reported 
that OPN is decreased in malignant tissue, but still detected 
in about half of tumours [7, 23, 26–28]. 
In the current study, we could not establish any statisti-
cally significant association between OPN immunostaining 
and the clinicopathological of EC. One of the few studies 
of OPN in EC reported similar findings [28]. However, in 
our study increased OPN immunostaining was reported in 
Table 3. Correlation between Clinicopathological features and OPN Immunostaining in tumours (n = 71)
Parameter
OPN Immunostaining (%)
P value
Low High
Age
< 60 years 15 (21.1%) 34 (47.9%)
0.262*
≥ 60 years 10 (14.1%) 12 (16.9%)
Histological type 
Endometrioid 22 (31%) 44 (62%)
0.136*
Serous 3 (4.2%) 2 (2.8%)
FIGO tumour grade
Low (Grade I) 13 (18.3%) 31 (43.6%)
0.184*
High (Grade II and III) 12 (16.9%) 15 (21.1%)
Tumour size
≤ 2 cm 14 (19.7%) 21 (26.9%)
0.488*
> 2 cm 12 (16.9%) 25 (35.2%)
Myometrial invasion
< 50% 18 (25.5%) 39 (54.9%)
0.168*
≥ 50% 7 (9.8%) 7 (9.8%)
Lymphovascular
Absent 24 (33.8%) 44 (62%)
0.908*
Present 1 (1.4%) 2 (2.8%)
Surgical resection margin
Free 23 (32.46%) 44 (62%)
0.380*
Involved 2 (5.6%) 2 (2.8%)
Lymph node metastasis
Absent 9 (12.8%) 24 (%)
0.838*Present 2 (2.8%) 2 (2.8%)
Not Sampled 34 (47.9%)
FIGO Staging
Early (Stage I and II) 19 (26.8%) 39 (54.9%)
0.347*
Late (Stage III and IV) 6 (8.5%) 7 (9.8%)
Local Recurrence
Absent 22 (31%) 38 (53.5%)
0.812*
Present 3 (4.2%) 8 (11.3%)
*Mann Whitney test
Figure 2. Overall survival curve (Kaplan Meier) according to OPN 
immunostaining 
High (increased) OPN immunostaining is associated with better 
overall survival [Log Rank (Mantel-Cox) = 4.385, p = 0.003]
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31 of low grade EC (43.6%) while in 15 high grade EC (21.1%) 
(p = 0.184). A previous report could not establish any relation 
between OPN and EC grade [28]. In a previous study, OPN 
immunostaining was shown to be increased with a higher 
tumour grade [23]. On the contrary, it was reported that 
high levels of OPN was associated with more differentiated 
tumours suggesting a protective role of OPN in EC [26].
In the present study, EC that invade less than 50% of 
myometrial thickness were positive in 80.3%, compared 
to a lower percentage (19.7%) in tumours invadeing more 
than 50% of myometrial thickness (p = 0.168). Although 
statistically not significant, however there is a trend that 
increased OPN immunostaining may be associated with 
less invading tumours. A study reported that high OPN is 
associated with lower stages [23]. In previous reports, silenc-
ing of OPN mRNA led to reduced invasion of EC cell lines in 
vitro and reduction of tumour size [1, 8, 29]. The statistical 
results from our study are not supporting this finding as 
there was no relation between OPN immunostaining and 
tumour stage or tumour size. In the current study, increased 
OPN immunostaining is significantly associated with higher 
overall survival probabilities. This result is in accordance with 
a previous report [26]. 
All together, our findings may support the trend that 
increased OPN immunostaining in EC may have good prog-
nostic outcomes. However, the conflicting results with the 
few reports may be due to different sample size, technical 
issues, and/or different cut-off point in immunohistochem-
istry interpretation. Therefore, for future consideration to 
stratify EC using OPN as prognostic molecular marker and 
therapeutic target, it has to be studied in the context of its 
multiple functions and different isoforms. Our study has 
a limitation of a relatively small number of patients and, 
therefore, should be expanded to confirm these findings.
 CONCLUSIONS
Our results showed that increased OPN immunostaining 
staining is considered a good predictor factor for survival 
outcome in EC and may have a role of future therapeutic 
management. The role of OPN as a molecular marker in 
EC is still unclear and needs to be established as it may be 
a possible target for future therapeutic applications in EC. 
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